ATTO-002

N/A

Report date: 2024/02/29 16:10:19

Base Information

Drug NameATTO-002

Drug Alias NameATTO-002

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-31 inhibitorsAnti-IL13

TargetsInterleukin-31Interleukin-13

Therapy Area/IndicationsFibrosisDermatitis, AtopicIdiopathic Pulmonary Fibrosis +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAttovia Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAttovia Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsFibrosisDermatitis, AtopicIdiopathic Pulmonary Fibrosis +[5]

Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A